Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales
Antimicrobial Agents and Chemotherapy · 07.01.2026 · 70 (1)
DOI: 10.1128/aac.00842-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.01.2026. Verfasst von Mariana Castanheira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Element Materials Technology (JMI Laboratories), North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: beta-Lactamases, Cefepime, Aztreonam, Cephalosporins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
We evaluated the activity of aztreonam-avibactam and comparators tested against 490 MBL-producing Enterobacterales isolates collected in 27 countries during 2019–2022. The most common MBL was NDM-1, which was detected among 307 isolates. The genes encoding NDM-5 and VIM-1 were detected among 68 and 53 isolates, respectively. Other 14 MBL-encoding genes or combinations were detected among 62 isolates. Mexico, Turkey, and Greece had the highest number of isolates (60, 59, and 57, respectively). All isolates were susceptible to aztreonam-avibactam (MIC 50/90 , 0.12/0.5 mg/L) when applying the EUCAST or FDA recently approved breakpoints (≤4 mg/L susceptible). Cefiderocol inhibited 66.7%/90.8% of the isolates when using EUCAST/FDA breakpoints. Cefepime-taniborbactam was active against 36.7%/55.5% of the isolates using the cefepime breakpoint for comparison purposes. Tigecycline and colistin inhibited 94.1% and 76.6% of the isolates (FDA and EUCAST breakpoints, respectively). The analysis of resistance mechanisms and genetic background of the MBL-producing isolates demonstrated genetic diversity among main species and presence of multiple resistance mechanisms including other β-lactamases, porin changes, and disruptions of efflux pump repressors. Aztreonam-avibactam was active despite the presence of these additional resistance mechanisms, but cefiderocol and cefepime-taniborbactam displayed variable activity. PBP3 YRIN and YRIK insertions were observed among 30 MBL-producing E. coli isolates. Aztreonam-avibactam MIC values ranged from 0.03 to 4 mg/L for these isolates, including an isolate carrying bla NDM-7 , bla CMY-42 , and porin changes. MBL-producing organisms are still considered an unmet medical need. Aztreonam-avibactam was active against this large collection of MBL-producing isolates that had elevated MIC values for many comparator agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Element Materials Technology (JMI Laboratories), North Liberty, Iowa, USA.
ORCID-Profile: Mariana Castanheira, John H Kimbrough, Helio S Sader
Förderung
- Pfizer
Zitieren
APA
Castanheira, M., Kimbrough, J. H., Morgan, G. M., Karr, M., & Sader, H. S. (2026). Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales. Antimicrobial Agents and Chemotherapy, 70(1). https://doi.org/10.1128/aac.00842-25
Vancouver
Castanheira M, Kimbrough JH, Morgan GM, Karr M, Sader HS. Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales. Antimicrobial Agents and Chemotherapy. 2026;70(1). doi:10.1128/aac.00842-25
BibTeX
@article{Castanheira2026,
author = {Castanheira, Mariana and Kimbrough, John H and Morgan, Gina M and Karr, Maura and Sader, Helio S},
title = {Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {1},
doi = {10.1128/aac.00842-25}
}
EUVIMED